Organization: Neuromed Pharmaceuticals

Merck and Neuromed ax drug development progra

Merck Frosst & Co and Vancouver-based Neuromed Pharmaceuticals have discontinued their collaboration on NMED-160, a Phase II compound for the treatment of chronic pain. The companies concluded that the compound did not have “the ideal pharmaceutical characteristics considered necessary to advance the compound further”. The two firms will continue their research collaboration evaluating alternate, earlier…

Neuromed raises US$25M for clinical development

Neuromed Pharmaceuticals has raised an additional US$25 million in a series D financing that brings its cumulative venture capital financing to $74 million. The new capital will be used to advance development of its lead compound for the treatment of chronic pain and its second development program for the treatment of anxiety, epilepsy and cardiovascular…